The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives
Section snippets
Historic development of fingolimod
Fingolimod (FTY720, GilenyaR, 2-amino-2[2-(4-octylphenyl)ethyl]-1,3-propanediol) was originally synthesized by the Japanese chemist Tetsuro Fujita from Yoshitomi Pharmaceutical Industries Ltd. (present Mitsubishi Tanabe Pharma Corporation, Japan) (Adachi et al., 1995) using the natural compound myriocin (ISP-1) as a lead. Myriocin was previously isolated by the same group from the culture broth of Isaria sinclairii, the imperfect or asexual stage of the genus Cordyceps sinclarii
Mechanism of action of fingolimod
The main immunomodulatory mechanism of action of fingolimod is based on its effect on lymphocyte homing. It reversibly redistributes T and B cells from the circulation to secondary lymphoid organs like peripheral and mesenteric lymph nodes and Peyer's patches, thereby causing a state of peripheral lymphopenia (Chiba et al., 1998). Since fingolimod resembles in chemical structure the sphingolipid molecule sphingosine, it can serve as a substrate for sphingosine kinase (SphK) to become
The S1P1 receptor
As outlined above and because of its binding to and activation of the various S1P receptor subtypes, except for S1P2, “active” fingolimod is pharmacologically considered an unselective S1P receptor agonist (Brinkmann, 2007, Brinkmann et al., 2002, Mandala et al., 2002). Moreover, it causes sustained desensitization of the S1P1-mediated signaling pathway by inducing receptor internalization and degradation, which on the cellular level results in functional antagonism. This effect of fingolimod
Pharmacokinetic characteristics of fingolimod
The pharmacokinetic characteristics of fingolimod as shown in Table 1 were summarized from the report NDA 22–527 submitted to the FDA for drug approval. A major advantage of fingolimod as a therapeutic agent is the possibility of oral application. Absorption is food-independent and slow (maximal plasma concentration after 12–16 h), but extensive, and its bioavailability is high (93%). It reaches steady-state concentrations after 1–2 months during daily intake (Clinical Pharmacology and
Fingolimod as a therapeutic agent
From its main effect to deplete peripheral lymphocytes, it is obvious that fingolimod has potential for the treatment of diseases associated with inappropriate immune responses, such as in allograft rejection and autoimmunity. First preclinical studies in rats, mice and dogs revealed a delay in allograft rejection with fingolimod alone and an even synergistic effect when used together with CSA (Chiba et al., 1996, Suzuki et al., 1996). It was then tested in several phase 1 to phase 3 clinical
Adverse effects of fingolimod
Table 2 summarizes some of the adverse events reported from patients with RRMS treated with low doses of 0.5 mg fingolimod daily for 24 months (FREEDOMS II). Those seen more frequently with fingolimod than with placebo included lymphopenia, increased liver transaminases, herpes viral infections, hypertension, and initial bradycardia and first degree AV block both as first-dose effects. Of note, analysis of pooled safety data from various phase 2 and phase 3 studies revealed that the risk for
Perspectives
Fingolimod was the first S1PR modulator reported to have immunosuppressive activity and it is so far the only one that was approved for clinical use. However, fingolimod is a nonspecific S1PR agonist and therefore new functionally related compounds have been developed, which better discriminate between the various S1PR subtypes and hence are expected to have improved efficacy and tolerability. These include the S1P1 selective compounds KRP-203, ponesimod and cenerimod, the S1P1 + 5 selective
Acknowledgments
This work was supported by the Swiss National Science Foundation (3100A0-111806).
Conflict of interest
None.
References (204)
- et al.
Design, synthesis, and structure-activity-relationships of 2-substituted-2-amino-1,3-propanediols - discovery of a novel immunosuppressant, FTY720
Bioorganic & Medicinal Chemistry Letters
(1995) - et al.
Sphingosine-1-phosphate lyase deficiency produces a pro-inflammatory response while impairing neutrophil trafficking
The Journal of Biological Chemistry
(2011) - et al.
FTY720 exerts a survival advantage through the prevention of end-stage glomerular inflammation in lupus-prone BXSB mice
Biochemical and Biophysical Research Communications
(2010) - et al.
FTY720: a novel approach to the treatment of hepatic ischemia-reperfusion injury
Transplantation Proceedings
(2002) - et al.
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy
Blood
(2009) - et al.
The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity
The Journal of Biological Chemistry
(2005) - et al.
Inflammatory bowel disease: cause and immunobiology
Lancet
(2007) - et al.
FTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells
The Journal of Biological Chemistry
(2009) - et al.
Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases
The Journal of Biological Chemistry
(2003) Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology
Pharmacology & Therapeutics
(2007)
The immune modulator FTY720 targets sphingosine 1-phosphate receptors
The Journal of Biological Chemistry
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
Lancet Neurology
Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications
American Heart Journal
Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound
Brain, Behavior, and Immunity
Ceramides - lipotoxic inducers of metabolic disorders
Trends in Endocrinology and Metabolism
A ceramide-centric view of insulin resistance
Cell Metabolism
Assessment of TRPM7 functions by drug-like small molecules
Cell Calcium
Unexpected cellular players in Rett syndrome pathology
Neurobiology of Disease
The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia
Biochemical and Biophysical Research Communications
Ceramide activates heterotrimeric protein phosphatase 2A
The Journal of Biological Chemistry
Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor
Cellular Signalling
Upregulation of the S1P3 receptor in metastatic breast cancer cells increases migration and invasion by induction of PGE2 and EP2/EP4 activation
Biochimica et Biophysica Acta
Targeting the correct HDAC(s) to treat cognitive disorders
Trends in Pharmacological Sciences
The sphingosine-1-phosphate receptor S1PR1 restricts sprouting angiogenesis by regulating the interplay between VE-cadherin and VEGFR2
Developmental Cell
Molecular cloning, tissue-specific expression, and chromosomal localization of a novel nerve growth factor-regulated G-protein- coupled receptor, nrg-1
Molecular and Cellular Neurosciences
EDG6, a novel G-protein-coupled receptor related to receptors for bioactive lysophospholipids, is specifically expressed in lymphoid tissue
Genomics
Characterization of a zebrafish (Danio rerio) sphingosine 1-phosphate receptor expressed in the embryonic brain
Biochemical and Biophysical Research Communications
Sphingosine kinase 2 deficient mice exhibit reduced experimental autoimmune encephalomyelitis: Resistance to FTY720 but not ST-968 treatments
Neuropharmacology
S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate
Chemistry & Biology
Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720
The Journal of Biological Chemistry
Ceramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an Acyl-CoA chain length-dependent manner
The Journal of Biological Chemistry
Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate
The Journal of Biological Chemistry
FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells
The Journal of Biological Chemistry
Sphingosine kinase-1 enhances endothelial cell survival through a PECAM-1-dependent activation of PI-3K/Akt and regulation of Bcl-2 family members
Blood
Treatment of chronic kidney diseases with histone deacetylase inhibitors
Frontiers in Physiology
Plasma sphingolipids and lung cancer: a population-based, nested case-control study
Cancer Epidemiology, Biomarkers & Prevention
New immunosuppresor strategies in the treatment of murine lupus nephritis
Lupus
New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth
Breast Cancer Research and Treatment
Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: discovery of (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime (LX2931) and (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932)
Journal of Medicinal Chemistry
Self-dsDNA in the pathogenesis of systemic lupus erythematosus
Clinical and Experimental Immunology
The sphingosine-1-phosphate modulator FTY720 targets multiple myeloma via the CXCR4/CXCL12 pathway
Clinical Cancer Research
Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics
The Biochemical Journal
Pathophysiological consequences of a break in S1P1-dependent homeostasis of vascular permeability revealed by S1P1 competitive antagonism
PLoS One
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Nature Reviews. Drug Discovery
The sphingosine-1-phosphate analog FTY720 reduces muscle ceramide content and improves glucose tolerance in high fat-fed male mice
Endocrinology
FTY720 (fingolimod) in renal transplantation
Clinical Transplantation
Discovery of APD334: design of a clinical stage functional antagonist of the sphingosine-1-phosphate-1 receptor
ACS Medicinal Chemistry Letters
Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice
The Journal of Clinical Investigation
Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation
Science
FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats
Transplantation Proceedings
Cited by (156)
The role of endothelial cell–pericyte interactions in vascularization and diseases
2024, Journal of Advanced ResearchBrain resident memory T cells rapidly expand and initiate neuroinflammatory responses following CNS viral infection
2023, Brain, Behavior, and ImmunitySphingolipids and impaired hypoxic stress responses in Huntington disease
2023, Progress in Lipid ResearchDeciphering the role of lipoproteins and lipid metabolic alterations in ageing and ageing-associated renal fibrosis
2023, Ageing Research ReviewsS1PR1 serves as a viable drug target against pulmonary fibrosis by increasing the integrity of the endothelial barrier of the lung
2023, Acta Pharmaceutica Sinica BSEW2871 reduces seizures via the sphingosine 1-phosphate receptor-1 pathway in the pentylenetetrazol and phenobarbitone kindling model of drug-refractory epilepsy
2024, Clinical and Experimental Pharmacology and Physiology